Gut Bacteria Helps Cancer-Causing Virus Suppress Immunity

New research has shown that commensal gut bacteria promotes the progression of leukemia caused by murine leukemia virus (MuLV) by enhancing the activity of genes that tamp down immune response.

Gut bacteria have a profound impact on health by aiding digestion, providing nutrients and metabolites, and working with the immune system to fend off pathogens. Some gut bacteria, however, have been implicated in progression of cancers of the gut and associated organs. In the latest example, a University of Chicago team has found that, in mice carrying both MuLV and commensal bacteria, three genes known as negative immune regulators are upregulated. Two of these three negative immune regulators are also known to be indicators of poor prognosis for humans with some forms of cancer.

“These two negative immune regulators have been really well documented to be poor prognostic factors in some human cancers, but nobody knew why,” says Tatyana Golovkina, PhD, Professor of Microbiology at University of Chicago and senior author of the study. “Using a mouse model of leukemia, we found that the bacteria contribute to upregulation of these negative immune regulators, allowing developing tumors to escape recognition by the immune system.”

In a 2011 study, Golovkina and her team found that a virus that causes mammary tumors in mice depends on gut bacteria, enabling the virus to block the immune responses from recognizing and eliminating infected cells. Thus, the microbes help the virus replicate and as a result, tumors develop.

In the new study, the researchers set out to see if commensal bacteria affected the development of a virus-induced cancer in another way besides assisting its replication. They used germ-free (GF) mice that had been raised in a special facility so they had no microbes, and specific pathogen free (SPF) mice that don’t have any pathogenic microbes that could causes disease but do have common commensal microbes, including bacteria that normally populate the gut. GF and SPF mice were both infected with the MuLV. While the virus infected and replicated equally well in both types of mice, only SPF mice developed high-frequency tumors.

Virally induced cancer cells all express viral antigens, or molecules that mark them as foreign to the host and make them the targets for the immune attack.  For the virally induced tumor cells to continue to replicate, they must be protected from the immune system’s attack, so, Golovkina’s team searched for a microbe-dependent immune evasion mechanism that enabled virally induced cancer cells to survive in the host.

The team performed a series of experiments with immunodeficient mice that were specially engineered, so they lacked the adaptive immune system. In the germ-free setting, these mice developed tumors when exposed to the virus with the same frequency as immunosufficient SPF mice with intact immune systems. So, the anti-tumor immune response was being counteracted by microorganisms, which were subsequently identified as commensal bacteria.

The researchers then found that commensal bacteria induced three genes known as negative immune regulators in infected mice. These genes normally act to shut down the immune system after it dealt with a pathogen, but in this case, they held back an immune response directed against cancer cells. Two of the three upregulated negative immune regulators—Serpinb9b and Rnf128—are also known to be indicators of poor prognosis for humans with some spontaneous cancers.

Not all commensal bacteria had tumor promoting properties, so Golovkina and her team are continuing to research more on why this immune suppressing capability only comes into play when both virus and bacteria are present.  “Now we have to figure out what’s so special about bacteria which have these properties,” she said.

The study, entitled “Gut commensal bacteria enhance pathogenesis of a tumorigenic murine retrovirus,” was published recently in the journal Cell Reports.